Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Meng, Li  [Clear All Filters]
Journal Article
Dou X, Zheng F, Zhang L, Jin J, Zhang Y, Liu B, Meng L, Zhu X, Lu Z, Jia Y, et al. Adolescents experienced more treatment failure than children with chronic myeloid leukemia receiving imatinib as frontline therapy: a retrospective multicenter study. Ann Hematol. 2021.
Hong L, Yuan L, Xu X, Ma Y, Meng L, Wang J, Zhao N, Wang X, Ma J. Biocompatible Nanotube-Strontium/polydopamine-arginine-glycine-aspartic acid coating on Ti6Al4V enhances osteogenic properties for biomedical applications. Microsc Res Tech. 2021.
Cao Y, Yi X, Wang N, Wang GX, Huang L, Hong Z, Meng L, Zhou X, Wang J, Hao X, et al. CD19/CD22 CAR T cell Cocktail Therapy Following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas: Combined CAR T Cell Therapy and Transplantation. Transplant Cell Ther. 2021.
Li Q, Zhong Z, Zeng C, Meng L, Li C, Luo Y, Wang H, Li W, Wang J, Cheng F, et al. A clinical observation of Chinese chronic myelogenous leukemia patients after discontinuation of tyrosine kinase inhibitors. Oncotarget. 2016.
Zhang X, Xu N, Yang Y, Lin H, Liu B, Du X, Liu X, Liang R, Chen C, Huang J, et al. Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study. Clin Lymphoma Myeloma Leuk. 2024.
Jiang Q, Li Z, Qin Y, Li W, Xu N, Liu B, Zhang Y, Meng L, Zhu H, Du X, et al. Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial. J Hematol Oncol. 2023;16(1):13.
Chen S, Meng L, Wang S, Xu Y, Chen W, Wei J. Effect assessment of a type of xeno-free and serum-free human adipose-derived mesenchymal stem cells culture medium by proliferation and differentiation capacities. Cytotechnology. 2023;75(5):403-420.
Meng L, Zhao P, Jiang Y, You J, Xu Z, Yu K, Boccaccini AR, Ma J, Zheng K. Extracellular and intracellular effects of bioactive glass nanoparticles on osteogenic differentiation of bone marrow mesenchymal stem cells and bone regeneration in zebrafish osteoporosis model. Acta Biomater. 2023.
Peng Y, Huang J, Yin J, Meng F, Cao Y, Huang L, Li D, Zhang Y, Zhang D, Meng L, et al. Frontline combination of dasatinib and low-intensity chemotherapy in adults with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia. Expert Rev Hematol. 2024.
Wang Y, Shi S, Liu H, Meng L. Hypoxia Enhances Direct Reprogramming of Mouse Fibroblasts to Cardiomyocyte-Like Cells. Cell Reprogram. 2016.
Yang S, Zhang X, Gale RPeter, Du X, Chen C-Y, Weng J-Y, Huang J, Li F, Zeng Y, Xiao Z, et al. Imatinib compared with second-generation tyrosine kinase-inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase. Am J Hematol. 2023.
Lv Q, Cao Y, Wang J, Meng L, Wang GX. Metagenomic Next-generation Sequencing May be a Tool for Timely Diagnosis of Seronegative and Primary Toxoplasma Infection After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report and Literature Review. Pediatr Infect Dis J. 2023.
Wu W, Zhou Q, Masubuchi T, Shi X, Li H, Xu X, Huang M, Meng L, He X, Zhu H, et al. Multiple Signaling Roles of CD3ε and Its Application in CAR-T Cell Therapy. Cell. 2020.
Chen H, Guo S, Xia Y, Yuan L, Lu M, Zhou M, Fang M, Meng L, Xiao Z, Ma J. The Role of Rho-GEF Trio in Regulating Tooth Root Development through the p38 MAPK Pathway. Exp Cell Res. 2018.
Zhang X, Gale RPeter, Liu B, Huang J, Zhang Y, Du X, Weng J, Li W, Xu N, Liu X, et al. Validation of the imatinib-therapy failure model. Leukemia. 2023.